Biotechnology company Immutrin has raised £65 ($86.7) million in Series A financing to help fund its lead asset through clinical proof of concept.  

Immutrin’s lead asset is targeting ATTR cardiomyopathy, a serious and potentially fatal form of amyloidosis.  

Amyloidosis is a group of rare, progressive diseases caused by misfolded proteins that aggregate into amyloid fibrils and accumulate in tissues and organs, leading to irreversible organ damage. Currently, there are no approved therapies that remove pre-existing amyloid deposits. Effective amyloid removal is regarded as critical to restoring organ function and improving clinical outcomes.  

Immutrin’s lead antibody candidate selectively binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response, enabling more efficient removal of established amyloid deposits. The antibody is primarily being developed to address ATTR but may also have the potential to treat other amyloidosis types, including rare forms. 

Mihriban Tuna, Chief Executive Officer at Immutrin, said: “Having been involved in building Immutrin from its earliest days, I’m delighted to welcome support from our new and existing investors in this strong global syndicate. The depth of investor confidence speaks to the strength of our approach, the clear differentiation of our lead asset, and the genuine opportunity to transform outcomes for patients with ATTR amyloidosis.” 

The Series A financing was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. 

James Topper, Managing Partner at Frazier Life Sciences, added: “We were delighted to lead this Series A financing and to support Immutrin at this pivotal stage. Our assessment of the landscape highlighted the compelling scientific foundations of the potential for Immutrin’s lead candidate to become a best-in-class therapy for reversal of ATTR amyloidosis. We look forward to collaborating with the Immutrin team to work towards advancing this asset to clinical proof of concept.”